Caris Life Sciences, Inc. Common Stock (CAI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.61B
Last updated: Nov 17, 2026 at 11:04 AM ET
Caris Life Sciences, Inc. Common Stock (CAI) Financials: Revenue, Profit and Cash Flow
Caris Life Sciences, Inc. Common Stock reported revenue of $812.03M for the fiscal year ended Dec 31, 2025, up 97.0% from the year before. That year, net income was -$68.09M with a net margin of -8.4%, operating cash flow was $83.16M and free cash flow was $66.89M. The quarter ended Sep 30, 2026 had revenue of $275.36M and net income of $15.25M.
Revenue and Margins
The operating margin was 5.6% in the fiscal year ended Dec 2025. Over the 10 years to Dec 2025, revenue grew from $249.67M, a compound annual rate of 12.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $812.03M | +97.0% | 66.4% | 5.6% | -8.4% |
| Dec 2024 | $412.26M | +34.7% | 43.4% | -62.4% | -68.4% |
| Dec 2023 | $306.13M | +18.4% | 29.2% | -104.4% | -111.5% |
| Dec 2022 | $258.49M | N/A | 31.0% | -122.2% | -124.1% |
| Dec 2020 | $294.01M | -29.4% | 62.6% | 47.3% | 9.4% |
| Dec 2019 | $416.54M | -3.6% | 48.1% | 31.3% | 7.4% |
| Dec 2018 | $432.10M | +24.0% | 49.4% | 34.4% | 18.2% |
| Dec 2017 | $348.39M | +18.4% | 48.6% | 30.3% | 20.7% |
| Dec 2016 | $294.35M | +17.9% | 46.7% | 22.4% | 2.0% |
| Dec 2015 | $249.67M | N/A | 50.4% | 27.3% | 10.7% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income fell 37.3% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $812.03M | $412.26M | $306.13M | $258.49M | $294.01M | $416.54M | $432.10M | $348.39M | $294.35M | $249.67M |
| Cost of revenue | $272.87M | $233.48M | $216.82M | $178.46M | $109.86M | $216.03M | $218.47M | $179.11M | $156.86M | $123.76M |
| Gross profit | $539.17M | $178.78M | $89.31M | $80.02M | $184.16M | $200.51M | $213.63M | $169.29M | $137.50M | $125.91M |
| Research and development | $101.58M | $113.92M | $116.88M | $101.27M | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $45.11M | -$257.12M | -$319.55M | -$315.76M | $139.09M | $130.28M | $148.78M | $105.67M | $65.96M | $68.09M |
| Net income | -$68.09M | -$281.89M | -$341.42M | -$320.83M | $27.73M | $31.01M | $78.60M | $72.06M | $6.00M | $26.84M |
| EBITDA | N/A | -$183.02M | -$266.68M | -$245.89M | $254.46M | $248.30M | $283.31M | $223.51M | $159.27M | $181.36M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 | Sep 2021 | Jun 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $275.36M | $263.71M | $216.17M | $292.89M | $216.83M | $181.40M | $120.92M | $101.62M | $100.05M | $80.68M | $100.83M | $85.69M |
| Gross profit | $182.28M | $179.60M | $141.35M | $220.91M | $147.51M | $113.69M | $57.06M | $44.41M | $37.55M | $26.11M | $54.09M | $42.87M |
| Operating income | $19.32M | $26.93M | $5.28M | $88.41M | $32.64M | -$17.99M | -$57.95M | -$60.84M | -$67.01M | -$92.22M | $66.44M | $50.84M |
| Net income | $15.25M | -$637.00K | -$510.00K | $81.96M | $24.32M | -$71.79M | -$102.58M | -$67.73M | -$66.19M | -$111.03M | $51.16M | $37.94M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $378.99M by $418.81M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.13B | $343.73M | $412.90M | $717.42M | $2.61B | $2.90B | $3.01B | $2.43B | $2.06B | $1.99B |
| Current assets | $997.80M | $215.73M | $242.61M | $516.04M | $214.66M | $499.13M | $220.02M | $140.34M | $135.15M | $144.11M |
| Cash and equivalents | $797.80M | $65.44M | $56.40M | $107.19M | $53.55M | $46.46M | $45.31M | $35.42M | $46.13M | $52.55M |
| Total liabilities | $548.36M | $620.92M | $2.56B | $2.42B | $1.91B | $2.21B | $2.31B | $1.87B | $1.60B | $1.53B |
| Short-term debt | $169.00K | $60.09M | $6.75M | $57.09M | $183.45M | $218.09M | $311.38M | $132.05M | $95.53M | $172.42M |
| Long-term debt | $378.82M | $319.44M | $166.11M | $169.57M | N/A | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | $577.31M | -$2.50B | -$2.14B | -$1.70B | $702.24M | $693.24M | $701.13M | $563.85M | $457.50M | $460.34M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.26B | $1.23B | $1.16B | $1.13B | $984.57M | $955.06M | $291.58M | N/A | N/A | N/A | $412.90M | $717.42M |
| Total liabilities | $616.14M | $637.89M | $568.90M | $548.36M | $506.21M | $502.15M | $2.89B | N/A | N/A | N/A | $2.56B | $2.42B |
| Cash and equivalents | N/A | $690.91M | $821.15M | $797.80M | $754.74M | $718.93M | $31.20M | N/A | N/A | N/A | $56.40M | $107.19M |
| Shareholder equity | $639.48M | $591.73M | $593.49M | $577.31M | $478.36M | $452.90M | -$2.60B | N/A | N/A | N/A | -$2.14B | -$1.70B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 80.4% of operating cash flow. Share repurchases came to 11.7% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $83.16M | -$245.20M | -$276.10M | -$285.71M | $277.02M | $254.00M | $179.77M | $155.19M | $129.26M | $147.37M |
| Capital expenditures | $16.26M | $8.44M | $22.32M | $42.26M | $219.45M | $319.14M | $812.84M | $502.18M | $251.25M | $389.41M |
| Free cash flow | $66.89M | -$253.64M | -$298.42M | -$327.96M | $57.57M | -$65.14M | -$633.07M | -$346.98M | -$121.99M | -$242.04M |
| Dividends paid | N/A | N/A | N/A | N/A | $17.71M | $8.83M | $3.26M | N/A | N/A | N/A |
| Share repurchases | $7.82M | $1.06M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$16.26M | $52.93M | $214.77M | -$282.99M | -$33.97M | -$271.87M | -$663.34M | -$411.75M | -$181.60M | -$305.25M |
| Financing cash flow | $664.99M | $200.29M | $10.13M | $10.45M | -$249.88M | -$108.48M | $512.35M | $245.63M | $46.60M | $156.54M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.25M | $28.48M | $32.88M | $44.78M | $62.42M | $7.29M | -$31.34M | -$38.92M | -$69.43M | -$62.93M | -$73.92M |
| Capital expenditures | $17.47M | $22.07M | $10.34M | $5.09M | $7.09M | $1.39M | $2.69M | $2.29M | $1.83M | $2.59M | $1.74M |
| Free cash flow | -$39.72M | $6.40M | $22.53M | $39.69M | $55.33M | $5.90M | -$34.03M | -$41.21M | -$71.25M | -$65.51M | -$75.66M |
Frequently Asked Questions About CAI
What is Caris Life Sciences, Inc. Common Stock's annual revenue?
Caris Life Sciences, Inc. Common Stock reported revenue of $812.03M for the fiscal year ended Dec 31, 2025.
How fast is Caris Life Sciences, Inc. Common Stock's revenue growing?
Revenue was up 97.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 46.5%.
Is Caris Life Sciences, Inc. Common Stock profitable?
No. Caris Life Sciences, Inc. Common Stock reported net income of -$68.09M for the fiscal year ended Dec 31, 2025, with a net margin of -8.4%.
How much free cash flow does CAI generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $83.16M minus capital expenditures of $16.26M produced free cash flow of $66.89M.
How much debt does Caris Life Sciences, Inc. Common Stock have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $378.82M, short-term debt of $169.00K and cash and equivalents of $797.80M.
CAI pages: Overview, Forecast, Financials, Valuation, Competitors